Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp Alfa in Thymoma and Thymic Carcinoma
NCT04417660Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2020
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in thymoma, thymic carcinoma (TC), sponsored by National Cancer Institute. Started Dec 2020; status: active, not recruiting.
02
Drugs
bintrafusp alfa
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT04417660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417660.